Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair

Cardiovascular Research

Volumn 79, Issue 4, 2008, Pages 611-620

  Kobayashi, Hiroyuki ^a   Minatoguchi, Shinya ^a   Yasuda, Shinji ^a   Bao, Narentuoya ^a   Kawamura, Itta ^a   Iwasa, Masamitsu ^a   Yamaki, Takahiko ^a   Sumi, Syohei ^a   Misao, Yu ^a   Ushikoshi, Hiroaki ^a   Nishigaki, Kazuhiko ^a   Takemura, Genzou ^a   Fujiwara, Takako ^b   Tabata, Yasuhiko ^c   Fujiwara, Hisayoshi ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO WOMEN'S UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Akt; Angiogenesis; Drug delivery system; Erythropoietin; Myocardial infarction; VEGF

Indexed keywords

ERYTHROPOIETIN RECEPTOR; GELATIN; GLYCOGEN SYNTHASE KINASE 3BETA; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HYDROGEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RABBIT; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, WESTERN; CARDIOVASCULAR AGENTS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DOSAGE FORMS; DRUG CARRIERS; ERYTHROPOIETIN, RECOMBINANT; FIBROSIS; GELATIN; HUMANS; HYDROGELS; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RABBITS; SIGNAL TRANSDUCTION; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 52449131191     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn154     Document Type: Article

References (36)

1. Kranz SB. Erythropoietin. Blood 1991;77:419-434.
2. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134- 148.
3. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. PNAS 2003;100:4802-4806.
4. Parsa CJ, Matsumori A, Kim J, Riel RU, Pascal LS, Walton GB et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
5. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and bepoetin. N Engl J Med 1998;339:584-590.
6. Khorana AA, Francis CW, Culakova E et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-2829.
7. Tabata Y, Hijikata S, Ikada Y. Enhanced vascularization and tissue granulation by basic fibroblast growth factor impregnated in gelatin hydrogels. J Control Release 1994;31:189-199.
8. Fukunaka Y, Iwanaga K, Morimoto K, Kakemi M, Tabata Y. Controlled release of plasmid DNA from cationized hydrogels based on hydrogel degradation. J Control Release 2002;80:333-343.
9. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, petrofski JA et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart. J Biochem 2004;279:20655-20662.
10. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 2005;19:243-250.
11. Hale SL, Setti C, Kloner RA. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol 2005;64:211-215.
12. Olea FD, Vera Janavel G, De Lorenzi A, Cuniberti L, Yannarelli G, Cabeza Meckert P et al. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J Cardiovasc Pharmacol 2006;47:736-741.
13. Kristensen J, Maeng M, Rehling M, Berg JS, Mortensen UM, Nielsen SS et al. Lack of acute cardioprotective administration in a porcine coronary occlusion model. Clin Physiol Funct Imaging 2005;25:305-310.
14. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004;18:1031-1033.
15. Hausenloy DJ, Duchen MR, Yellon DM. Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce Stat5 DNA binding activity. EMBO J 1995;14:2005-2013.
16. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 2001;98: 9050-9055.
17. Stephanou A. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem 2000;275: 10002-10008.
18. Hausenly DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 2005;288:H971-H976.
19. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA et al. Inhibition of myocardial injury by ischemic post-conditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H578-H588.
20. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of 'modified reperfusion' protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004;95:230- 232.
21. Juhaszova M, Zorov DB, Kim SH, Pepe SS, Fu Q, Fishbein KW et al. Glycogen synthase kinase-3 beta mediates convergence of protection signaling to inhibit mitochondrial permeability transition pore. J Clin Invest 2004; 113:1535-1549.
22. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischemia-reperfusion injury. Cardiovasc Res 2003;60:617-625.
23. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Cardiovasc Res 2004;61:372-384.
24. Kaga S, Zhan L, Altaf E, Maulik N. Glycogen synthase kinase 3β/β-catenin promotes angiogenis and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and surviving expression in rat ischemic preconditioned myocardium. J Mol Cell Cardiol 2006;40:138-147.
25. Heeschen C, Aicher A, Lehmann R, Fichtlischer S, Vasa M, Urbich C et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-1346.
26. Takeshita S, Zheng LP, Brogi E, Keamey M, Pu LO, Bunting S et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994;9:662-670.
27. Asahara T, Takahashi T, Matsuda H, Kalka C, Chen D, Iwaguro H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18: 3964-3972.
28. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007;100:662-669.
29. George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI3-kinase-dependent manner. Cardiovasc Res 2005;68:299-306.
30. Goldstein P. Controlling cell death. Science 1997;275:1081- 1082.
31. Hattori R, Hernandez TE, Zhu L, Maulik N, Kaneda Y, Das DK. An essential role of the antioxidant gene Bcl-2 in myocardial adaptation to ischemia: an insight with antisense Bcl-2 therapy. Antioxid Redox Signal 2001;3: 403-413.
32. Reemers EEJM, Cleutjens JPM, Smith JFM, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2002;89:201-210.
33. Spinale FG. Matrix metalloproteinases: regulation and dysregulation on the failing heart. Circ Res 2002;90:520-530.
34. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei-Kim et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000;102:246-252.
35. Minatoguchi S, Takemura G, Chen XH, Wang N, Uno Y, Koda M et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarct granulocyte colony-stimulating factor treatment. Circulation 2004;109:2572-2580.
36. Jacoby JJ, Kalinowski A, Liu MG, Zhang SS, Gao Q, Chai GX et al. Cardiomyocyte-restricted knockout of Stat3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 2003;100:12929-12934.